Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Empagliflozin and losartan renal hemodynamic crossover study in type 2 diabetes
2019-003141-15Phase 4Completed
- Sponsor
- Amsterdam University Medical Center
- Start
- Jun 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of empagliflozin and losartan in type 2 diabetes mellitus (T2DM) (4 arms), sponsored by Amsterdam University Medical Center. Primary endpoint: Change in glomerular filtration rate. Started Jun 2020; status: completed.
02
Drugs
empagliflozinlosartan
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on 2019-003141-15.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-003141-15.